An Immunosurveillance Mechanism Controls Cancer Cell Ploidy

Laura Senovilla(Université Paris-Sud), Ilio Vitale(Université Paris-Sud), Isabelle Martins(Université Paris-Sud), Maximilien Tailler(Université Paris-Sud), Claire Pailleret(Université Paris-Sud), Mickaël Michaud(Université Paris-Sud), Lorenzo Galluzzi(Université Paris-Sud), Sandy Adjemian(Université Paris-Sud), Oliver Kepp(Université Paris-Sud), Mireia Niso‐Santano(Université Paris-Sud), Shensi Shen(Université Paris-Sud), Guillermo Mariño(Université Paris-Sud), Alfredo Criollo(Université Paris-Sud), Alice Boilève(Université Paris-Sud), Bastien Job(Institut Gustave Roussy), Sylvain Ladoire(Inserm), François Ghiringhelli(Inserm), Antonella Sistigu(Université Paris-Sud), Takahiro Yamazaki(Université Paris-Sud), Santiago Rello‐Varona(Université Paris-Sud), Clara Locher(Université Paris-Sud), Vichnou Poirier-Colame(Université Paris-Sud), Monique Talbot(Institut Gustave Roussy), Alexander Valent(Génomes, biologie cellulaire et thérapeutiques), Francesco Berardinelli(Roma Tre University), Antonio Antoccia(Roma Tre University), Fabiola Ciccosanti(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani), Gian María Fimia(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani), Mauro Piacentini(University of Rome Tor Vergata), Antonio Fueyo(Universidad de Oviedo), Nicole L. Messina(The University of Melbourne), Ming Li(Peter MacCallum Cancer Centre), Christopher J. Chan(Peter MacCallum Cancer Centre), Verena Sigl(Institute of Molecular Biotechnology), Guillaume Pourcher(Université Paris-Sud), Christoph Ruckenstuhl(Research Institute of Molecular Pathology), Didac Carmona‐Gutiérrez(Research Institute of Molecular Pathology), Vladimir Lazar(Institut Gustave Roussy), Josef Penninger(Institute of Molecular Biotechnology), Frank Madeo(Research Institute of Molecular Pathology), Carlos López-Otı́n(Universidad de Oviedo), Mark J. Smyth(Peter MacCallum Cancer Centre), Laurence Zitvogel(Université Paris-Sud), Maria Castedo(Université Paris-Sud), Guido Kroemer(Délégation Paris 5)
Science
September 28, 2012
Cited by 426Open Access
Full Text

Abstract

Cancer cells accommodate multiple genetic and epigenetic alterations that initially activate intrinsic (cell-autonomous) and extrinsic (immune-mediated) oncosuppressive mechanisms. Only once these barriers to oncogenesis have been overcome can malignant growth proceed unrestrained. Tetraploidization can contribute to oncogenesis because hyperploid cells are genomically unstable. We report that hyperploid cancer cells become immunogenic because of a constitutive endoplasmic reticulum stress response resulting in the aberrant cell surface exposure of calreticulin. Hyperploid, calreticulin-exposing cancer cells readily proliferated in immunodeficient mice and conserved their increased DNA content. In contrast, hyperploid cells injected into immunocompetent mice generated tumors only after a delay, and such tumors exhibited reduced DNA content, endoplasmic reticulum stress, and calreticulin exposure. Our results unveil an immunosurveillance system that imposes immunoselection against hyperploidy in carcinogen- and oncogene-induced cancers.


Related Papers